Placebo (Saxagliptin) — Competitive Intelligence Brief

Placebo (Saxagliptin) (Placebo (Saxagliptin)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: DPP-4 inhibitor. Area: Diabetes.

phase 3 DPP-4 inhibitor DPP-4 Diabetes Small molecule

Target snapshot

Placebo (Saxagliptin) (Placebo (Saxagliptin)) — AstraZeneca. Saxagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which works by increasing the levels of incretin hormones to stimulate the release of insulin and decrease the release of glucagon.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Placebo (Saxagliptin) TARGET	Placebo (Saxagliptin)	AstraZeneca	phase 3	DPP-4 inhibitor	DPP-4
DPP-4 inhibitor + metformin group	DPP-4 inhibitor + metformin group	Beni-Suef University	marketed	DPP-4 inhibitor + biguanide combination	DPP-4 enzyme; metformin acts on multiple targets including mitochondrial glycerophosphate dehydrogenase
alogliptin and actoplus met	alogliptin and actoplus met	The Fourth Affiliated Hospital of Zhejiang University School of Medicine	marketed	DPP-4 inhibitor + biguanide combination	DPP-4 enzyme; metformin acts on multiple targets including mitochondrial glycerophosphate dehydrogenase
SGLT2i+Metformin+Cofrogliptin	SGLT2i+Metformin+Cofrogliptin	Huazhong University of Science and Technology	marketed	SGLT2 inhibitor + Biguanide + DPP-4 inhibitor (fixed-dose combination)	SGLT2, mitochondrial complex I, DPP-4
Anagliptin BID Treatment	Anagliptin BID Treatment	JW Pharmaceutical	marketed	DPP-4 inhibitor	Dipeptidyl peptidase-4 (DPP-4)
MET + Vildagliptin Group	MET + Vildagliptin Group	Hospital de Clinicas de Porto Alegre	marketed	Combination antidiabetic agent (biguanide + DPP-4 inhibitor)	Metformin: mitochondrial glycerophosphate dehydrogenase; Vildagliptin: DPP-4 (dipeptidyl peptidase-4)
SGLT2 inhibitor and DPP-4 inhibitor	SGLT2 inhibitor and DPP-4 inhibitor	LMC Diabetes & Endocrinology Ltd.	marketed	SGLT2 inhibitor and DPP-4 inhibitor combination	SGLT2 (sodium-glucose cotransporter 2) and DPP-4 (dipeptidyl peptidase-4)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (DPP-4 inhibitor class)

1. Merck Sharp & Dohme LLC · 5 drugs in this class
2. Daewoong Pharmaceutical Co. LTD. · 4 drugs in this class
3. AstraZeneca · 4 drugs in this class
4. LG Life Sciences · 2 drugs in this class
5. Tanabe Pharma Corporation · 2 drugs in this class
6. Ain Shams University · 2 drugs in this class
7. Ono Pharmaceutical Co. Ltd · 2 drugs in this class
8. Cinnagen · 1 drug in this class
9. GRADE Study Group · 1 drug in this class
10. CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · 1 drug in this class